Emerging data suggest Retatrutide , a dual activator targeting both incretin and glucose-dependent insulinotropic polypeptide , appears to offer a promising step forward for obesity loss . Preliminary human investigations have demonstrated considerable decreases in visceral fat , potentially exceeding current obesity treatments. However , more stud